Division of Neurosurgery, Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan.
Division of Human Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
World Neurosurg. 2020 Sep;141:91-100. doi: 10.1016/j.wneu.2020.05.240. Epub 2020 Jun 4.
In the revised World Health Organization 2016 classification of central nervous system tumors, "diffuse midline glioma, H3 K27M-mutant" has been added as a new diagnostic entity. However, some confusion exists concerning this diagnostic entity because H3 K27M-mutant diffuse midline glioma is diagnosed with grade IV regardless of morphologic phenotype. Furthermore, the significance of H3 K27M mutation in tumors that aren't typical "diffuse midline glioma, H3 K27M-mutant," such as those with an unusual location and nontypical histology, remains unclear.
To elucidate further such unusual tumors, we describe here a rare case of pediatric low-grade glioma located in the tectum, which was morphologically a pilocytic astrocytoma (PA) with genetically H3 K27M mutation but no microvascular proliferation, necrosis, mitoses, or other genetic alterations, insofar as we were able to observe. At the latest follow-up, 28 months after surgery, radiotherapy, and chemotherapy, the patient was found to be free from any neurologic deficits and MRI demonstrated that the tumor was stable without tumor regrowth. This case might be identified as "diffuse midline glioma, H3 K27M-mutant", grade IV, when applying only the current World Health Organization 2016 classification. In addition, we discuss the morphologically benign gliomas harboring the H3 K27M mutation based on the literature.
We describe here a rare case and present a short literature review of circumscribed/nondiffuse gliomas, particularly in PA with H3 K27M mutation. However, the significance of H3 K27M mutation for PA remains unclear, so further studies and clinical data are needed to elucidate the biology and optimal treatment of such tumors.
在世界卫生组织 2016 年修订的中枢神经系统肿瘤分类中,新增了“弥漫性中线胶质瘤,H3 K27M 突变型”作为一种新的诊断实体。然而,由于 H3 K27M 突变型弥漫性中线胶质瘤无论形态表型如何均诊断为 4 级,因此人们对这一诊断实体存在一些混淆。此外,H3 K27M 突变在非典型“弥漫性中线胶质瘤,H3 K27M 突变型”肿瘤中的意义,如位置异常和非典型组织学的肿瘤中的意义仍不清楚。
为了进一步阐明这些不典型肿瘤,我们在此描述了一例罕见的儿童低级别胶质瘤病例,位于脑桥,形态上为毛细胞星形细胞瘤(PA),具有 H3 K27M 基因突变,但无微血管增生、坏死、有丝分裂或其他遗传改变,就我们所能观察到的而言。在最新的随访中,即手术后 28 个月,进行了放化疗,患者没有任何神经功能缺损,磁共振成像显示肿瘤稳定,没有肿瘤复发。仅根据目前的世界卫生组织 2016 年分类,该病例可能被确定为“弥漫性中线胶质瘤,H3 K27M 突变型”,4 级。此外,我们根据文献讨论了具有 H3 K27M 突变的形态学良性胶质瘤。
我们在此描述了一例罕见病例,并对局限性/非弥漫性胶质瘤,特别是 H3 K27M 突变的 PA 进行了简短的文献复习。然而,H3 K27M 突变在 PA 中的意义仍不清楚,因此需要进一步的研究和临床数据来阐明此类肿瘤的生物学和最佳治疗方法。